爱美客 (300896)

IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.

ASZ

Tags

300ESG Index300 Non-Cyclical IndexMSCI Component StocksSpecialized-Sophisticated-Distinctive-Innovative EnterprisesCSI 200 IndexCSI A100 IndexCSI Leading Enterprises IndexMedical DevicesMedical CosmetologyMedical Aesthetics ConceptPharmaceuticals and HealthcareGuozheng Growth IndexGuozheng Corporate Governance IndexLarge Cap GrowthPrivate Enterprises 100 IndexHundred-Yuan StocksBelow Additional Issuance PriceHigh-Performing StocksIndustry LeadersNon-Cyclical StocksChiNext InnovationChiNext Large CapChiNext 50 IndexChiNext IndexChiNext HealthcareSZSE 100 IndexSZSE 300 IndexSZSE Growth IndexSZSE Governance IndexSZSE Defensive 50 IndexSZSE Medicine Equal Weight IndexBrand Engineering IndexSZSE 100 Equal Weight IndexZhongchuang Equal Weight IndexJuchao Large-cap IndexShenzhen A-Share Pharmaceutical IndexBOC International CSI 300 ESG IndexChiNext Equal Weight IndexCSI 300 Quality IndexChiNext Composite IndexCSI All-share Pharmaceutical Sector IndexEmerging Technology 100 IndexSZSE Emerging Industries IndexZhongchuang Growth IndexSZSE 1000 IndexSZSE 300 Return IndexCSI 1000 Growth IndexSZSE Component Index ReturnCSI 300 Equal Weight IndexCSI 300 ESG IndexLarge & Mid-cap IndexCSWD Life Sciences IndexShanghai-Hong Kong-Shenzhen 300 IndexCNI 1000 IndexXingyin Wealth Management Balanced 300 IndexCS Beijing-Tianjin-Hebei IndexBiomedicine IndexCSI Medical IndexExcellent Performance Strategy IndexSZSE Performance IndexGrowth 40 IndexChiNext Value IndexChiNext Registration SystemSeptember 2021 Lock-up ExpiryShareholding Increase CommitmentCSI 300 Non-cyclical IndexCNI Emerging Industries IndexTechnology 50 IndexTechnology 50 Strategy IndexCS High-end Manufacturing IndexAdvanced Manufacturing IndexCSI 300 Shenzhen Market IndexZhongchuang 100 Return IndexSZSE Technology IndexCSI 300 ESG Leading IndexSZSE 100 Return IndexChiNext Quality IndexSZSE High Beta IndexSustainable Development IndexCSI 300 Growth IndexSZSE Pharmaceutical IndexDividend Quality IndexCSI 800 IndexCS Pharmaceutical TI Index100 Performance IndexESG 100 IndexCSI 300 Preferred IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexCNI 300 IndexCCTV 500 IndexCSI 300 USD (CNH) IndexChiNext Basic IndexSZSE Private Enterprises IndexHua Xia Bank ESG IndexCS Pharmaceutical Innovation IndexChina United Quality Growth IndexSZSE Component Pharmaceutical IndexZhongguancun 60 IndexCSI All-share Pharmaceutical IndexCSI 300 USD IndexSZSE Pharmaceutical 50 IndexSmart Select 300 ESG Leading IndexSZSE 300 Equal Weight IndexChiNext Low Volatility IndexSZSE Component Index Equal WeightPharmaceutical & Health 100 IndexCSI 300 Pharmaceutical IndexSME & ChiNext Q IndexCSI 700 IndexMid-small Cap IndexPharmaceutical 50 IndexZhongchuang High Beta IndexZhongchuang Low Volatility IndexPharmaceutical 50 Strategy IndexChiNext High Beta IndexChiNext Manufacturing IndexChiNext Growth IndexESG 300 IndexCR New Momentum IndexOrient Securities Competition IndexChiNext Return IndexJuchao Mid-cap IndexChiNext Emerging IndexCSI 300 Growth Innovation IndexChiNext Growth IndexPerformance Index

K-Line Chart

No K-line data available

Company NameIMEIK Technology Development Co., Ltd.
Listing Date2020-09-28
Issue Price118.27RMB
Registered Capital30259.206110k RMB
Legal RepresentativeJian Jun
Registered AddressRoom 416B, 4th Floor, Beikong Technology Building, No. 10 Baifuquan Road, Changping Science Park, Beijing, China
IndustryMedical Aesthetics
Main BusinessThe company is an innovative leading enterprise in the field of biomedical soft tissue repair materials in China. Based on the research, development, and transformation of biomedical materials, the company is dedicated to the development of biopharmaceuticals such as recombinant proteins and peptides.
Company ProfileIMEIK Technology Development Co., Ltd. (hereinafter referred to as "the Company") is a national high-tech enterprise specializing in the research, development, production, and sales of biomedical materials. The Company's self-developed and approved products, including Yimei, Bonita, Aifulai, Heshou, and Yimei Plus One, all use sodium hyaluronate as the main base material, combined with polymer composite materials such as hydroxypropyl methylcellulose and polyvinyl alcohol gel microspheres, as well as various nutrients like amino acids and vitamins. These products fully leverage the synergistic and complementary effects of the materials, each having distinct characteristics in terms of indications, injection depth, and injection experience. The aforementioned products are all Class III medical devices used for repairing facial and neck wrinkles. The Company is the first domestic enterprise to obtain medical device registration certificates for such products. Guided by customer and market demands, the Company relies on years of technological accumulation and extensive transformation experience, supported by research and development platforms for biomedical materials such as the Beijing Engineering Laboratory for Biodegradable New Materials. It adheres to technological innovation, continuously increases R&D investment, constantly improves its technical level and innovation capabilities, and maintains its leading edge in products and technology.

Stock Details

1. Key Indicators

  • Total Shares(W): 30259.21
  • Circulating A-Shares(W): 20859.16
  • Earnings Per Share(RMB): 3.6300
  • Net Assets Per Share(RMB): 24.4246
  • Operating Revenue(W RMB): 186496.60
  • Total Profit(W RMB): 128028.11
  • Net Profit Attributable to Parent(W RMB): 109326.35
  • Net Profit Growth Rate(%): -31.05
  • Weighted Return on Equity(%): 14.1800
  • Operating Cash Flow Per Share(RMB): 3.5450
  • Undistributed Profit Per Share(RMB): 13.0923
  • Capital Reserve Per Share(RMB): 11.2042

2. Main Business

The main business covers:

  • Research, development and transformation of biomedical materials and biopharmaceutical products.

3. Company Basic Information

  • Company Name: Imeik Technology Development Co., Ltd.
  • Listing Date: 2020-09-28
  • Industry: Pharmaceuticals & Healthcare - Medical Aesthetics
  • Address: 21F, Tower C, Shimao Building, No. A92 Jianguo Road, Chaoyang District, Beijing
  • Website: www.imeik.net
  • Company Profile: The company is an innovative leader in the field of biomedical soft tissue repair materials in China. Based on the research, development and transformation of biomedical materials, and committed to the development of recombinant proteins and polypeptides and other biopharmaceuticals, the company has successfully industrialized injectable hyaluronic acid series products and poly-p-dioxanone facial implant threads, and has established product technology transformation platforms for biomedical materials such as medical chitosan and polylactic acid. Product clinical applications cover medical aesthetics, surgical repair and metabolic disease treatment. The company is the first domestic enterprise to obtain the National Medical Products Administration (NMPA) approval for an injectable hyaluronic acid medical device product registration certificate for facial soft tissue repair. As of the end of the reporting period, the company had five NMPA-approved Class III injectable hyaluronic acid series products, making it the company with the most approved similar products by the NMPA. The company's five products differ in formulation components, injection sites, and injection experience, meeting consumer demand in multiple market segments. In addition, the company obtained the Class III medical device registration certificate for poly-p-dioxanone facial implant threads in May 2019, which is the first facial implant thread product approved by the NMPA.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Xiamen Zhixin Junxing Investment Partnership (Limited Partnership) General Legal Person 1942.81 9.31
2 Xiamen Danrui Investment Partnership (Limited Partnership) General Legal Person 1467.90 7.04
3 Xiamen Keshishang Investment Partnership (Limited Partnership) General Legal Person 1295.21 6.21
4 Hong Kong Securities Clearing Company Ltd. Northbound Funds 682.95 3.27
5 HuaBao CSI Healthcare Sector Index ETF Fund 425.89 2.04
6 E Fund ChiNext Index ETF Fund 293.34 1.41
7 Huatai-PineBridge CSI 300 Index ETF Fund 267.73 1.28
8 China Merchants Guozheng Bio-medicine Index Securities Investment Fund (LOF) Class A Fund 196.03 0.94
9 Yongying CSI Total Return Medical Devices ETF Fund 93.17 0.45
10 Tianhong Guozheng Bio-medicine ETF Fund 68.82 0.33

5. Concept Sectors

  • Medical Aesthetics Concept
  • Weight Loss Drugs
  • Synthetic Biology
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • Industry Leader
  • Hundred-Yuan Stocks
  • MSCI Constituent
  • Specialized, Refined, Distinctive, and Innovative SMEs
  • Below Issue Price
  • Non-Cyclical Stocks
  • Zhongchuang 100
  • ChiNext Index
  • Mid-Cap Growth
  • SZSE 100
  • SZSE 300
  • Technology 100
  • SZSE Governance
  • Consumption 100
  • SZSE Governance Index
  • SZSE Growth Index
  • SZSE Growth
  • CSI 300
  • ChiNext 300
  • CSI 200
  • 300 Non-Cyclical
  • SZSE Innovation
  • ChiNext Innovation
  • ChiNext Large Cap
  • ChiNext Quality
  • ChiNext Healthcare
  • Innovation 100
  • 300 ESG

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information